Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Immunoglobulin G (IgG) is the dominant antibody isotype in human serum and appears in four variants: IgG1, IgG2, IgG3 and IgG4. Given their critical role in the immune system, IgGs are a major ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

There were no clinically significant reductions in other immunoglobulins including IgG3, IgA, IgE, or IgM compared to baseline. Based upon the rapid and deep reductions of total IgG observed with ...

Here, the authors report sustained immune memory and increased IgG1 and IgG3 antibodies six years following one dose of quadrivalent HPV vaccine in Fijian girls.

FcγRIIIa alleles with valine at position 158 show a higher binding affinity for IgG1, whereas alleles with phenylalanine at position 158 show a higher binding affinity for IgG3 and IgG2. Comprehensive ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...

There were no clinically significant reductions in IgG3, IgA, IgE, IgM, or albumin, nor clinically significant increases in AST, ALT, bilirubin, or cholesterol. Upcoming milestones: ...

The clinical presentation is a spectrum of symptoms, including fever and chills, which are the most common symptoms in both AHTR and DHTR. [7] Hypotension, tachycardia, nausea and vomiting are ...